TY - JOUR
T1 - Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID
AU - Faghy, Mark A.
AU - Wüst, Rob C. I.
AU - Altmann, Daniel M.
AU - Ashton, Ruth E. M.
AU - McMullen, Sarah Barley
AU - Duncan, Rae
AU - Ewing, Andrew G.
AU - Hausmann, Elke
AU - Gupta, Sanjay
AU - Hornig, Mady
AU - Joffe, David
AU - Kane, Binita
AU - Khan, M. Asad
AU - Natt, Micheal
AU - Owen, Rebecca
AU - Putrino, David
AU - Skipper, Lindsay
AU - Taylor, Claire
AU - Thomas, Callum
AU - Tuller, David
AU - Beckman, Danielle
AU - Kruger, Arneaux
AU - Pretorius, Etheresia
N1 - Publisher Copyright:
© The Author(s) 2026.
PY - 2026/12/1
Y1 - 2026/12/1
N2 - Background: Viral and infectious illnesses can exert profound and enduring effects on population health and well-being. In the aftermath of SARS-CoV-2 infection, post-acute sequelae, collectively referred to as Long COVID, have emerged as a major global health challenge, affecting more than 400 million people and contributing to estimated annual economic costs exceeding $1 trillion. Scope of the review: Long COVID encompasses a wide and heterogeneous spectrum of debilitating symptoms, including cognitive dysfunction, sleep disturbances, severe fatigue, and post-exertional malaise. Despite its substantial burden, fundamental uncertainties remain regarding its underlying pathophysiology, the development of robust diagnostic criteria, and the identification of effective therapeutic options. Key insights: This review synthesises current evidence on the biological mechanisms thought to contribute to Long COVID, spanning immune dysregulation, viral persistence, autonomic dysfunction, microvascular pathology, and other emerging hypotheses. We examine advances and limitations in contemporary diagnostic approaches and critically appraise existing treatment strategies, highlighting inconsistencies and gaps that hinder clinical consensus. Implications: By integrating interdisciplinary insights, this review underscores the urgent need for mechanistic clarity, validated diagnostic frameworks, and rigorously evaluated treatment pathways. Addressing these gaps will be essential to developing effective, evidence-based management strategies and mitigating the long-term impact of Long COVID on global health.
AB - Background: Viral and infectious illnesses can exert profound and enduring effects on population health and well-being. In the aftermath of SARS-CoV-2 infection, post-acute sequelae, collectively referred to as Long COVID, have emerged as a major global health challenge, affecting more than 400 million people and contributing to estimated annual economic costs exceeding $1 trillion. Scope of the review: Long COVID encompasses a wide and heterogeneous spectrum of debilitating symptoms, including cognitive dysfunction, sleep disturbances, severe fatigue, and post-exertional malaise. Despite its substantial burden, fundamental uncertainties remain regarding its underlying pathophysiology, the development of robust diagnostic criteria, and the identification of effective therapeutic options. Key insights: This review synthesises current evidence on the biological mechanisms thought to contribute to Long COVID, spanning immune dysregulation, viral persistence, autonomic dysfunction, microvascular pathology, and other emerging hypotheses. We examine advances and limitations in contemporary diagnostic approaches and critically appraise existing treatment strategies, highlighting inconsistencies and gaps that hinder clinical consensus. Implications: By integrating interdisciplinary insights, this review underscores the urgent need for mechanistic clarity, validated diagnostic frameworks, and rigorously evaluated treatment pathways. Addressing these gaps will be essential to developing effective, evidence-based management strategies and mitigating the long-term impact of Long COVID on global health.
UR - https://www.scopus.com/pages/publications/105038010506
U2 - 10.1038/s43856-025-01300-z
DO - 10.1038/s43856-025-01300-z
M3 - Article
C2 - 42056279
SN - 2730-664X
VL - 6
JO - Communications medicine
JF - Communications medicine
IS - 1
M1 - 255
ER -